Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisation

被引：0
|
作者：
Patel, H. [1 ]
Khalid, J. M. [1 ]
Shah, S. [2 ]
Shah, R. [3 ]
Berger, A. [2 ]
机构：
[1] Takeda Dev Ctr Europe Ltd, Evidence & Value Generat, London, England
[2] Evidera, Real World Evidence, Waltham, MA USA
[3] Evidera, Real World Evidence, London, England
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P552
引用
收藏
页码：S385 / S386
页数：2
相关论文
共 50 条
  • [41] REAL-WORLD COMPARISON OF ARTHRALGIAS WITH INFLIXIMAB VS. VEDOLIZUMAB IN THE TREATMENT OF BIO-NAIVE INFLAMMATORY BOWEL DISEASE
    Ritter, Timothy
    Fourment, Chris
    Kuten, Samantha
    Van Anglen, Lucinda
    GASTROENTEROLOGY, 2020, 158 (03) : S4 - S4
  • [42] COMPARISON OF REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AMONG ADVANCED THERAPY-NAIVE PATIENTS WITH ULCERATIVE COLITIS INITIATED ON USTEKINUMAB OR VEDOLIZUMAB
    Zhdanava, Maryia
    Kachroo, Sumesh
    Boonmak, Porpong
    Burbage, Sabree
    Shah, Aditi
    Korsiak, Jill
    Lefebvre, Patrick
    Kerner, Caroline
    Pilon, Dominic
    GASTROENTEROLOGY, 2024, 166 (05) : S1422 - S1423
  • [43] Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center
    Allamneni, Chaitanya
    Venkata, Krishna
    Yun, Huifeng
    Xie, Fenglong
    DeLoach, Lindsey
    Malik, Talha A.
    GASTROENTEROLOGY RESEARCH, 2018, 11 (01) : 41 - 45
  • [44] Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naive Patients with Ulcerative Colitis
    Lee, Yong Il
    Park, Yehyun
    Park, Soo Jung
    Kim, Tae Il
    Kim, Won Ho
    Cheon, Jae Hee
    GUT AND LIVER, 2021, 15 (02) : 232 - 242
  • [45] REAL-WORLD COSTS IN BIOLOGIC-NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE
    Kaplan, D.
    Ung, B.
    Pelletier, C.
    Udeze, C.
    Tian, M.
    VALUE IN HEALTH, 2019, 22 : S888 - S888
  • [46] Real-World Use of Secukinumab Among Biologic-NaiVe and Biologic-Experienced Patients with Ankylosing Spondylitis in the United States
    Oelke, Kurt R.
    Garg, Rahul
    Li, Yunfeng
    Liu, Xing
    Zhou, Huanxue
    Park, Yujin
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [47] TREATMENT DISCONTINUATION, FLARES, AND HOSPITALIZATIONS AMONG BIOLOGIC-NAiVE PATIENTS WITH IBD OVER THE FIRST YEAR OF TREATMENT: A "REAL-WORLD" COMPARATIVE EFFECTIVENESS STUDY OF VEDOLIZUMAB VERSUS INFLIXIMAB
    Patel, Haridarshan
    Raluy-Callado, Mireia
    Berger, Ariel
    Curtis, Rebecca
    Khalid, Javaria Mona
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S78 - S79
  • [48] Real-World Effectiveness and Onset of Action of Vedolizumab as a First-Line Biologic in Biologic-Naïve Patients With Ulcerative Colitis
    Anyanwu, Precious A.
    Van Anglen, Lucinda J.
    Chou, Chiahung
    Sanchirico, Marie
    Ritter, Timothy E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S876 - S877
  • [49] Secukinumab Therapy in Biologic-naive vs. Biologic-experienced Patients: Real-world Effectiveness, Persistence and Safety Results from the Rheumatic Diseases Portuguese Registry
    Azevedo, Soraia
    Tavares-Costa, Jose
    Laires, Pedro
    Garcia, Salome
    Nero, Patricia
    Pestana, Jorge
    Martins-Martinho, Joana
    Silva, Ana Bento
    Rodrigues, Joana
    Sequeira, Graca
    Costa, Emanuel
    Santos, Filipe Cunha
    Furtado, Carolina
    Santos, Bernardo
    Raposo, Ana
    Saraiva, Liliana
    Samoes, Beatriz
    Barcelos, Filipe
    Santos, Maria Jose
    Santos, Helena
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3829 - 3831
  • [50] vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn's disease - a meta-analysis
    Yiu, T. H.
    Leong, R.
    Ko, Y.
    Pudipeddi, A.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 694 - 694
12345